Business Wire

Coming in From the Cold: Needle-free Patch Technology for Mrna Vaccines Aims to End Need for Frozen Storage and Improve Access

CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines. Vaxxas’ vaccine-delivery platform could improve access to ...
Business Insider

UPDATE - Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles

SAN FRANCISCO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable ...
BioWorld

Vaxxas, CEPI advance program for thermostable mRNA vaccines

Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA vaccines using Vaxxas’ needle-free high-density microarray patch.
The Scientist

Microarrays R Us - for the Moment

In this issue we take a close look at DNA microarrays, the current amore of biological and biomedical researchers. There's little reason to doubt that the infatuation will continue, at least for ...